Glaukos Takes Another Hit From CMS; Investors Respond Negatively As Stock Falls
The US Medicare agency's new rule for facility fees brings more bad news for Glaukos; Wells Fargo downgrades company’s stock in response.
You may also be interested in...
Rate adjustment recommendations to US Medicare could result in less drastic reimbursement cuts for Glaukos than those currently on the table.
The US Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that includes new reimbursement levels for multiple medical devices, including the Glaukos iStent.
The Affordable Care Act requires health insurers to cover contraceptives; some lawmakers in the US House want to make sure those requirements are upheld.